Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years Novartis (Press Release) 5d
Novartis reports positive results from Phase III ALIGN trial for IgAN Clinical Trials Arena 4d Vanrafia The Lancet Pharma
ASCO 2026: Mixed Sclc result for Legend’s LB2102, Novartis expedites manufacture Pharmaceutical Technology 7d Biotech Biotechnology Pharma All sources
Novartis Cosentyx shows sustained remission in polymyalgia rheumatica RTT News 5d Cosentyx Biotech Pharma
